UCB
CompanyBelgiumFounded 1928
UCB develops 3 assets, the furthest approved (levetiracetam in epilepsy). Mostly antibody and small molecule acting on SV2A and SOST; based in Belgium, founded in 1928.
- 3
- Assets
- Furthest
- Approved
- 71
- Trials
- 2
- Signals
Pipeline
3Binds synaptic vesicle protein SV2A to modulate neurotransmitter release and reduce seizures.
Approved, Small molecule, SV2A, epilepsy, Epilepsy, Idiopathic Generalized
Inhibits sclerostin to promote bone formation and reduce bone resorption
Approved, Antibody, SOST, osteoporosis, osteogenesis imperfecta (Phase 3)
Phase 2, Antibody, chronic obstructive pulmonary disease with chronic bronchitis
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
12 assets, 3 trials
In the full profile
- Evidence behind the mechanisms4
- Trials106
- Signals3
- Similar companies6
Updated 13 Oct 2026 · 184 sources